12-Nov-2025 3:05 PM CST - Business Wire Bicycle Therapeutics to Participate in the Jefferies London Healthcare Conference Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today announced that management will participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, Nov. 18, at 10:30 a.m. GMT. A live webcast of the fireside chat will be accessible from the Investor section of the companys website at w
30-Oct-2025 6:00 AM CST - Business Wire Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2025 Financial Results Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today reported financial results for the third quarter ended September 30, 2025, and provided recent corporate updates. We are currently seeking broad regulatory feedback to make an informed decision on our path forward with zelenectide pevedotin in metastatic ur
8-Aug-2025 6:00 AM CST - Business Wire Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2025 Financial Results Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today reported financial results for the second quarter ended June 30, 2025, and provided recent corporate updates. We continue to execute on our strategy, which is grounded in scientific rigor and focused on fulfilling our mission to develop next-generation prec
1-May-2025 6:00 AM CST - Business Wire Bicycle Therapeutics Reports Recent Business Progress and First Quarter 2025 Financial Results Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today reported recent business progress and financial results for the first quarter ended March 31, 2025. In the first quarter, we continued to advance our business priorities and our pipeline of oncology therapeutics. We were pleased to share additional human im
1-Apr-2025 6:00 AM CST - Business Wire Bicycle Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today announced that management will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Tuesday, April 8, at 12:45 p.m. ET. A live webcast of the fireside chat will be accessible from the Investor section of the companys we
25-Feb-2025 6:00 AM CST - Business Wire Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2024 Financial Results Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided recent corporate updates. In 2024, the significant progress across our pipeline and business continued to validate our approach to developing next-generati
13-Jan-2025 6:00 AM CST - Business Wire Bicycle Therapeutics Announces Updated Topline Zelenectide Pevedotin Data and Highlights 2025 Strategic Priorities and Milestones Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today announced updated topline Phase 1 combination data for zelenectide pevedotin plus pembrolizumab in previously untreated (first-line) cisplatin-ineligible patients with metastatic urothelial cancer (mUC). The company also announced recent accomplishments and
9-Jan-2025 6:00 AM CST - Business Wire Bicycle Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today announced that management will participate at the 43rd Annual J.P. Morgan Healthcare Conference in a podium presentation on Tuesday, Jan. 14, at 5:15 p.m. PT, followed by a question-and-answer breakout session at 5:35 p.m. PT. A live webcast of the presentat
12-Dec-2024 5:30 PM CST - Business Wire Bicycle Therapeutics Announces Data Updates Across Zelenectide Pevedotin Program and Development Strategy Leveraging NECTIN4 Gene Amplification Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today announced the presentation of data showing the enhanced anti-tumor activity of zelenectide pevedotin monotherapy in breast cancer patients with NECTIN4 gene amplification at the 2024 San Antonio Breast Conference Symposium (SABCS) in San Antonio, Texas. The
12-Nov-2025 3:05 PM CST - Business Wire Bicycle Therapeutics to Participate in the Jefferies London Healthcare Conference Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today announced that management will participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, Nov. 18, at 10:30 a.m. GMT. A live webcast of the fireside chat will be accessible from the Investor section of the companys website at w
30-Oct-2025 6:00 AM CST - Business Wire Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2025 Financial Results Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today reported financial results for the third quarter ended September 30, 2025, and provided recent corporate updates. We are currently seeking broad regulatory feedback to make an informed decision on our path forward with zelenectide pevedotin in metastatic ur
8-Aug-2025 6:00 AM CST - Business Wire Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2025 Financial Results Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today reported financial results for the second quarter ended June 30, 2025, and provided recent corporate updates. We continue to execute on our strategy, which is grounded in scientific rigor and focused on fulfilling our mission to develop next-generation prec
1-May-2025 6:00 AM CST - Business Wire Bicycle Therapeutics Reports Recent Business Progress and First Quarter 2025 Financial Results Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today reported recent business progress and financial results for the first quarter ended March 31, 2025. In the first quarter, we continued to advance our business priorities and our pipeline of oncology therapeutics. We were pleased to share additional human im
1-Apr-2025 6:00 AM CST - Business Wire Bicycle Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today announced that management will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Tuesday, April 8, at 12:45 p.m. ET. A live webcast of the fireside chat will be accessible from the Investor section of the companys we
25-Feb-2025 6:00 AM CST - Business Wire Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2024 Financial Results Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided recent corporate updates. In 2024, the significant progress across our pipeline and business continued to validate our approach to developing next-generati
13-Jan-2025 6:00 AM CST - Business Wire Bicycle Therapeutics Announces Updated Topline Zelenectide Pevedotin Data and Highlights 2025 Strategic Priorities and Milestones Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today announced updated topline Phase 1 combination data for zelenectide pevedotin plus pembrolizumab in previously untreated (first-line) cisplatin-ineligible patients with metastatic urothelial cancer (mUC). The company also announced recent accomplishments and
9-Jan-2025 6:00 AM CST - Business Wire Bicycle Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today announced that management will participate at the 43rd Annual J.P. Morgan Healthcare Conference in a podium presentation on Tuesday, Jan. 14, at 5:15 p.m. PT, followed by a question-and-answer breakout session at 5:35 p.m. PT. A live webcast of the presentat
12-Dec-2024 5:30 PM CST - Business Wire Bicycle Therapeutics Announces Data Updates Across Zelenectide Pevedotin Program and Development Strategy Leveraging NECTIN4 Gene Amplification Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today announced the presentation of data showing the enhanced anti-tumor activity of zelenectide pevedotin monotherapy in breast cancer patients with NECTIN4 gene amplification at the 2024 San Antonio Breast Conference Symposium (SABCS) in San Antonio, Texas. The
